Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novacea falls after ending Asentar trial

NOVC lost $4.30 (60%) to $2.89 on Monday after it ended the Phase III ASCENT-2 trial of Asentar (DN-101) to treat

Read the full 218 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE